China SXT Pharmaceuticals, Inc.
SXTC
$4.11
$0.8124.55%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
--
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -87.83% | -705.07% | -253.06% | -551.47% | -6.62% |
| Total Depreciation and Amortization | -5.53% | -43.81% | -51.70% | -47.81% | -44.42% |
| Total Amortization of Deferred Charges | -- | -37.26% | 156.77% | 106.68% | 77.87% |
| Total Other Non-Cash Items | 252.62% | 278.98% | 191.09% | 224.37% | 27.52% |
| Change in Net Operating Assets | -145.96% | -49.37% | 15.64% | -19.96% | -154.66% |
| Cash from Operations | -71.29% | -33.80% | -1.30% | -9.77% | -21.65% |
| Capital Expenditure | -- | 77.78% | 71.43% | 71.43% | 71.43% |
| Sale of Property, Plant, and Equipment | -- | -76.46% | -38.42% | 123.15% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -15,865.22% | -6,800.00% | -2,058.90% | -- |
| Cash from Investing | -2,066.98% | -2,039.28% | -2,002.11% | -1,235.50% | 140.91% |
| Total Debt Issued | -93.23% | -93.09% | -92.96% | -18.96% | 413.79% |
| Total Debt Repaid | 80.36% | -64.10% | -493.40% | -10.21% | 52.19% |
| Issuance of Common Stock | 417.73% | 705.39% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 78.42% | 62.02% | 29.68% | -22.46% |
| Cash from Financing | 71.84% | 19.99% | -28.01% | 131.50% | 420.04% |
| Foreign Exchange rate Adjustments | 1,452.45% | 19.31% | -132.62% | -102.99% | 91.48% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 66.00% | -2.81% | -61.91% | 397.37% | 214.38% |